GCT is characterized by a stromal cell population, which is thought to be a mesenchymal osteoblast precursor, and variable numbers of eponymous giant cells. The giant cells are CD4 + and CD68 + , positive for tartrate-resistant acid phosphatase and other markers of true osteoclasts, which is consistent with their hemopoietic origin.
Mononuclear osteoclast-like cells can also be observed, which presumably represent precursor cells. The mesenchymal cell population is typically mononuclear and expresses vimentin. It is thought that the mesenchymal cell is the neoplastic component of GCT. 1 Treatment of GCT depends on the stage of the disease, and is generally based on uncontrolled and retrospective studies (reviewed by Thomas and Skubitz 2 ). In most cases, definitive treatment involves surgical curettage. 3 Local adjuvant therapies may be employed to reduce the risk for relapse. Such adjuvant treatments include packing the cavity with bone cement, where the thermogenic polymerisation of methylmethacrylate may kill residual tumor cells. 4 The local relapse rates for curettage vary between 20 and 50%. En bloc excision of tumors may also be used, with appropriate reconstruction of the adjacent joint. 3 This process, which carries a higher morbidity, reduces the relapse rates to about 10%. Surgical excision may be associated with unacceptable morbidity, for example with large sacral lesions, lesions affecting the spine, large lesions extending into soft tissues, or metastatic lung lesions. Radiotherapy may be useful, and is associated with 60-80% local control rates. 5 However, in addition to other long-term morbidities associated with radiotherapy in young patients, 
Bone Biology and RANKL
Bone is a complex, dynamic structure undergoing constant remodeling throughout life (reviewed by Martin et al. 10 and Sims et al. 11 ). Excess bone resorption is a major contributor to bone and joint diseases. 12 Osteoporosis, or generalized loss of bone mass, is a common disease and a significant health burden. The major problems that arise are due to fractures in the elderly, leading to immobility and a substantial mortality.
Osteoporosis is due to an excess of bone resorption over formation, and is most commonly seen in women. In general, peak bone mass is 
RANKL and Giant Cell Tumor of Bone
Expression of RANKL in GCT of bone was first observed by two groups. 31, 32 These investigators showed that stromal cells within GCT express RANKL, and that co-culture of stromal cells with the RAW264. Interestingly, RANKL is expressed in several osteoclast-enriched neoplastic diseases, including GCT of tendon sheath, 35 reparative giant cell granuloma, 37 and giant-cell-rich hepatoma, 38 suggesting that RANKL may be the final common pathway mediating osteoclast-like cell recruitment in a range of giant-cell-rich tumor types.
Denosumab
Atkins and colleagues observed that OPG treatment dose dependently inhibited resorption of bone slices by GCT in culture, and could also inhibit the formation of multinucleated osteoclasts from precursors within the GCT. 31, 39 These effects of OPG were competitively reversed by increasing concentrations of exogenous RANKL. This observation, and those outlined above, raised the possibility that blockade of RANKL may provide clinical benefit in GCT. However, the use of recombinant OPG itself may be associated with the generation of autoimmunity to the endogenous gene product, as has been observed for patients treated with recombinant human erythropoietin. 40 Denosumab is a fully human profound and sustained effect on suppression of bone turnover, with marked lowering of alkaline phosphatase, and urinary collagen Ctelopeptide. 42 The investigators observed that serum calcium levels were transiently suppressed to some degree, and this was accompanied by increases in serum PTH levels. There was a strong effect to increase bone mass measured at various sites and total body bone mass in this study.
These effects appeared to be to some degree dose-dependent, with a maximum effect seen with 60mg subcutaneous doses. The authors also noted that a sustained effect on total bone mass was seen with sixmonthly dosing, although C-telopeptide levels started to increase by three months, and a greater effect on bone mass was observed with monthly treatments. Two subsequent large-scale randomized trials 
Denosumab and Giant Cell Tumor of Bone
A proof-of-principle study of denosumab in GCT has recently been reported. 45 The target population were patients with recurrent or unresectable GCT. 
Summary
There are no effective systemic therapies for unresectable or recurrent 
